Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of chronic moderate-to-severe atopic dermatitis (AD) for at least 1 year
Recent history of inadequate response to medicated topical therapy for AD or required systemic therapy to control disease
Moderate-to-severe AD defined as affected BSA at least 10%, IGA at least 3, EASI at least 16, Peak Pruritus NRS at least 4
You may not be if
A current or past medical history of conditions associated with thrombocytopenia, coagulopathy, or platelet dysfunction
Currently have active forms of other inflammatory skin diseases, i.e. not AD, or have evidence of skin conditions (e.g. psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that would interfere with evaluation of AD or response to treatment
Participants who have received prior treatment with any systemic JAK inhibitors
Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication within specified time frames prior to the first dose of study medication, including topical treatments that could affect AD
Pregnant or breastfeeding women or sexually-active women of childbearing potential who are unwilling to use contraception
Clareo Health | Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
